(S)-Veliflapon  (Synonyms: (S)-BAY X 1005; (S)-DG-031)

(S)-Veliflapon ((S)-BAY X 1005; (S)-DG-031) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC₅₀ values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood^[1][2][3].

(S)-Viliflapon decreases leukotriene B4 (LTB4) synthesis in human whole blood with dose-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

361.43

Solid

C₂₃H₂₃NO₃

128253-32-7

O=C(O)[[email protected]@H](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3

Room temperature in continental US; may vary elsewhere.

• [1]. Fruchtmann R, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions. 1993 Mar;38(3-4):188-95.  [Content Brief]

  [2]. Hermann, David J., et al. Dosing schedules of leukotriene synthesis inhibitors for human therapy. World Intellectual Property Organization. WO2009002746.

  [3]. Helgadottir, et al. Polymorphisms in the susceptibility genes for myocardial infarction, stroke, and peripheral artery occlusive disease and their use in risk assessment and prophylaxis therapy. United States. US20070280917.